CRON · Cronos Group Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Cronos delivered record Q2 2026 net revenue of $53.0 million (+58% YoY, +51% organic constant currency), record gross profit of $28.5 million (+96% YoY), and record adjusted EBITDA of $13.1 million, while a new Israeli anti-dumping investigation was initiated on August 5, 2026, posing a risk to its Israel business.
- + Net revenue rose 58% YoY to a record $53.0 million, up 51% on an organic constant-currency basis.
- + Israel delivered a 10th consecutive quarter of record net revenue, up 60% YoY (32% constant currency), with Peace Naturals leading the medical market.
- + International segment ex-Israel grew net revenue 88% YoY, led by strong demand for Peace Naturals in Germany.
- + Spinach held the #1 overall vape brand position in Canada for a second consecutive quarter with share expanding to 10.6% and remained #1 in edibles for an eighth consecutive quarter.
- + Repurchased 12.3 million shares in the first half of 2026 while ending the quarter with $827 million in cash, equivalents and deposits and positive operating cash flow.
- − The Israel Ministry of Economy and Industry initiated a new anti-dumping investigation on August 5, 2026, following a new complaint filed July 30, 2026, after the prior investigation was terminated on procedural grounds without a substantive determination.
- − Operating expenses rose $1.2 million YoY to $21 million, with $0.5 million of the increase from CanAdelaar transaction costs.
- − Israel net revenue growth of 60% as reported was largely driven by foreign exchange, with constant-currency growth of only 32%.
- − Pending CanAdelaar acquisition remains open pending Dutch regulatory clearance, taking longer than originally hoped.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRON
this stock
Cronos Group Inc.
|
$1.21B | +25.5% | +24.6% | 17.3 | 0.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRON | -2.9% | -2.4% | +29.4% | -2.1% | +25.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -2.3% | -2.5% | +17.2% | -1.5% | +13.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.